Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroGen, Inc - Common Stock (NQ:FGEN)

5.270 -0.030 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FibroGen, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stocks Modestly Lower; Dow Looks To Extend Losing Streak
Stocks are modestly below breakeven this afternoon. 
Via Talk Markets
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Crude Oil Rises; Carnival Shares Drop After Q2 Results
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 80 points on Monday. The Dow traded down 0.02% to 33,719.54 while the NASDAQ fell 0.53% to 13,420.67. The S&P 500, also... 
Via Benzinga
Is the Stock Market Closed on the Fourth of July 2023?
Investors are looking for information about the stock market being closed on the Fourth of July and we've got the answers they seek! 
Via InvestorPlace
FibroGen Shares Are Tumbling After Another Pamrevlumab Trial Setback
FibroGen Inc (NASDAQ: FGEN) shares are trading lower after the company 
Via Benzinga
FibroGen's Return on Invested Capital Overview
Via Benzinga
FibroGen's Anemia Candidate Fails In Myelodysplastic Syndrome Study
Via Benzinga
FibroGen Earnings Preview
Via Benzinga
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
Via Benzinga
FibroGen's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for FibroGen
Via Benzinga
Is the Stock Market Closed on July 3, 2023?
Investors are preparing for Independence Day and that has some traders wondering if the stock market is closed on July 3, 2023. 
Via InvestorPlace
Insiders Promise Not to Sell AMTD Digital (HKD) Stock Until 2025
AMTD Digital (HKD) stock is on the move Monday after insiders promised not to sell shares on the public market for a few more years. 
Via InvestorPlace
Why Is FibroGen (FGEN) Stock Down 81% Today?
FibroGen (FGEN) stock is heading lower on Monday after the company's Phase 3 clinical trial failed to meet its primary endpoint. 
Via InvestorPlace
FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug
This is the company's second high-profile failure this month. 
Via Investor's Business Daily
US Stocks Edge Higher; Goldman Sachs Downgrades Tesla To Neutral
U.S. stocks traded slightly higher this morning, with the Dow Jones gaining around 25 points on Monday. Following the market opening Monday, the Dow traded up 0.08% to 33,753.64 while the NASDAQ rose... 
Via Benzinga
Earnings Preview For FibroGen
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for... 
Via Benzinga
FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost
The company's lead drug didn't improve upper-limb mobility for some patients with the disease. 
Via Investor's Business Daily
FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal
FibroGen Inc (NASDAQ: FGEN) announced topline data from the Phase 3 LELANTOS-1 trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy (DMD)  
Via Benzinga
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
Via MarketBeat
FibroGen Shares Gain As Analyst Creates Bullish Pitch On Pulmonary Fibrosis Opportunity
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
Via Benzinga
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.